Gene Therapy for Heart Failure? AskBio Trial Offers Hope for a Single Dose

DURHAM, NC – April 01, 2026 – In a development that could mark a turning point for cardiovascular medicine, AskBio has completed enrollment for its GenePHIT Phase 2 clinical trial. The study is evaluating AB-1002, an investigational gene therapy aimed at treating heart failure, a relentless condition that affects an estimated 64 million people worldwide and for which a cure remains elusive. The completion of enrollment, with the final of 173 participants now randomized, is a critical milestone that moves the novel treatment one step closer to a potential new reality for patients.

AskBio, a gene therapy company operating as a subsidiary of Bayer AG, confirmed that the trial is now fully underway, with initial results anticipated in the first half of 2027. This advancement brings a potential paradigm shift in treatment into sharper focus: a single-dose therapy designed to address the underlying mechanics of a failing heart.

A New Frontier in Heart Failure Treatment

For decades, the management of heart failure with reduced ejection fraction (HFrEF) has relied on a cocktail of daily medications and, in advanced cases, implantable devices. While these therapies have improved outcomes, they primarily manage symptoms and slow progression. AB-1002 represents a fundamentally different approach. It is a one-time gene therapy, administered directly to the heart via a single intracoronary infusion, that aims to correct a biological malfunction at its source.

The therapy uses a specially designed adeno-associated virus (AAV) vector to deliver a gene that promotes the production of a protein called inhibitor-1. This protein is engineered to block protein phosphatase 1 (PP1), an enzyme whose overactivity is linked to the poor pump function seen in heart failure. By targeting this specific mechanism, AB-1002 is designed to improve the heart's ability to contract and pump blood efficiently.

This innovative strategy is not just theoretical. It is built on promising data from a Phase 1 trial, the results of which were published in the prestigious journal Nature Medicine in late 2025. In that smaller, early-stage study of 11 participants, AB-1002 was found to be generally well-tolerated, with no serious adverse events deemed related to the treatment. More importantly, the trial showed encouraging signals of efficacy, with most participants demonstrating clinically meaningful improvements in left ventricular ejection fraction (a key measure of heart function) and a reduction in the severity of their symptoms as measured by the New York Heart Association (NYHA) functional class.

The Rigor of GenePHIT and the Path Forward

The now-fully-enrolled GenePHIT trial is designed to rigorously test the promise of AB-1002 on a much larger scale. As a Phase 2 adaptive, double-blinded, placebo-controlled study, it represents the gold standard in clinical research, designed to minimize bias and produce robust evidence. Its 173 participants are spread across 46 sites in the United States, Canada, and several European nations, ensuring the data reflects a diverse patient population.

Participants in the trial are adults with non-ischemic cardiomyopathy and NYHA Class III heart failure—a stage where patients experience significant limitations in activity and symptoms even with minimal exertion, despite receiving standard medical care. They will be randomized to receive either a low or high dose of AB-1002 or a placebo, in addition to their existing treatments.

“Heart failure is a major public health challenge and places a massive strain on healthcare systems around the world,” said Dr. Timothy D. Henry, the GenePHIT Principal Investigator. “Prevalence is increasing, and the need for innovative therapies has never been greater. Completing enrollment in this trial brings us another step closer to evaluating a potential treatment strategy for heart failure with reduced ejection fraction.”

Bayer's Strategic Bet on Gene Therapy

The significance of the GenePHIT trial extends beyond the cardiology clinic and into the boardrooms of global pharmaceuticals. AskBio was acquired by the German life sciences giant Bayer AG in 2020 in a deal valued at up to $4 billion, signaling a massive strategic investment in the future of medicine. Bayer's move was a clear bet that gene therapy, once confined to treating rare genetic disorders, is ready to tackle common, complex diseases like heart failure.

A successful outcome for AB-1002 would be a monumental victory for Bayer, validating its high-stakes acquisition and its broader multi-billion-dollar strategy to build a world-leading cell and gene therapy platform. The commercial opportunity is immense; a one-time curative or long-lasting treatment for a condition affecting tens of millions would not only generate substantial revenue but would also cement Bayer’s position at the forefront of medical innovation, reshaping its portfolio for decades to come.

Hope for Millions Living in the Shadow of Heart Failure

For the millions of patients and their families, the clinical and corporate stakes translate into something far more personal: hope. Living with heart failure is a daily struggle against debilitating symptoms like shortness of breath, profound fatigue, and fluid retention that can make simple tasks feel monumental. The disease carries a heavy psychological burden and a prognosis that can be worse than many cancers.

Even with optimal guideline-directed medical therapy, many patients with Class III heart failure continue to decline, facing frequent hospitalizations and a diminished quality of life. The completion of enrollment means that a potential new avenue of treatment is being actively and thoroughly investigated.

“AskBio’s Phase 2 heart failure program investigates the efficacy and safety of AB-1002, which is designed to potentially mitigate the symptoms of heart failure with reduced ejection fraction and improve survival rates and quality of life,” noted Dr. Canwen Jiang, Chief Development Officer and Chief Medical Officer at AskBio. “The data we receive from the participants will help us better understand the potential of our investigational gene therapy in an area of significant medical need.”

While AB-1002 remains an investigational therapy, and its ultimate success is not guaranteed, the completion of trial enrollment is a tangible step forward. The global medical community now watches and waits for the data readout in 2027. If the promise seen in early studies holds true in this larger, more definitive trial, it could herald a new era in cardiovascular medicine, transforming the future for millions of people with failing hearts.